Labor/Employment
Jan. 16, 2026
Boehringer Ingelheim faces whistleblower retaliation suit over biosimilar safety concerns
A former 20-year employee alleges he was fired after repeatedly raising concerns about potential contamination in Boehringer Ingelheim's Cyltezo, a biosimilar version of Humira. The lawsuit seeks damages for retaliation, wrongful termination, and emotional distress.
Multinational pharmaceutical company Boehringer Ingelheim is being sued by a former employee of 20 years who claims he was fired in retaliation for whistleblowing on safety and regulatory concerns related to a drug's development.
In a complaint filed Wednesday in Alameda County Superior Court, Brian Coloma alleges the company repeatedly ignored or suppressed warnings about potential contamination risks to a biosimilar version of the autoimmune drug Humira, marketed as Cyltezo....
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In